Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 10,882B 68.78B 61.71B 57.05B 51.67B 96.53B 6,551B 97.7B 682B 272B 3,428B 258B 253B P/E 2026 *
21.4x
P/E 2027 * 18.9x
Enterprise Value 9,884B 62.47B 56.05B 51.82B 46.93B 87.68B 5,950B 88.74B 620B 247B 3,113B 234B 229B EV / Sales 2026 *
7.1x
EV / Sales 2027 * 6.42x
Free-Float
38.12%
Yield 2026 *
2.01%
Yield 2027 * 2.3%
1 day+0.59%
1 week+0.59%
Current month+6.88%
1 month+9.14%
3 months-5.88%
6 months-18.03%
Current year-19.29%
1 week 6,522
Extreme 6522
6,897
1 month 5,974
Extreme 5974
6,897
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,259
Extreme 4259
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%+0.59%-2.35%+52.87% 68.78B
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.39%+2.32%+54.07%+66.27% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+2.18%+2.48%+34.09%+56.07% 294B
+0.89%-0.66%+2.66%+26.19% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.55%+1.41%+36.79%+74.09% 410.59B
Weighted average by Cap. +0.52%+1.51%+44.09%+88.49%

Financials

2026 *2027 *
Net sales 1,392B 8.8B 7.9B 7.3B 6.61B 12.35B 838B 12.5B 87.28B 34.77B 439B 33.03B 32.33B 1,520B 9.61B 8.62B 7.97B 7.22B 13.48B 915B 13.65B 95.27B 37.95B 479B 36.05B 35.29B
Net income 509B 3.22B 2.89B 2.67B 2.42B 4.52B 307B 4.57B 31.93B 12.72B 160B 12.08B 11.83B 575B 3.64B 3.26B 3.02B 2.73B 5.1B 346B 5.17B 36.07B 14.37B 181B 13.65B 13.36B
Net Debt -998B -6.31B -5.66B -5.23B -4.74B -8.85B -601B -8.96B -62.56B -24.92B -314B -23.67B -23.17B -1,125B -7.11B -6.38B -5.9B -5.34B -9.98B -677B -10.1B -70.49B -28.08B -354B -26.67B -26.11B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
29/10/26 JP¥6,653.00 +0.59% 4,547,300
28/10/26 JP¥6,614.00 -1.11% 3,542,700
27/10/26 JP¥6,688.00 -3.03% 3,220,000
26/10/26 JP¥6,897.00 +1.50% 3,324,200
23/10/26 JP¥6,795.00 +2.74% 5,542,700
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,614.00JPY
Average target price
8,440.00JPY
Spread / Average Target
+27.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Chugai Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4519 Stock